Sage Therapeutics Enters Material Definitive Agreement
| Field | Detail |
|---|---|
| Company | Sage Therapeutics, Inc. |
| Form Type | 8-K |
| Filed Date | Jun 16, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, filing
TL;DR
Sage Therapeutics signed a big deal on 6/13/25, filing an 8-K.
AI Summary
On June 13, 2025, Sage Therapeutics, Inc. entered into a material definitive agreement. The company also provided a Regulation FD disclosure and filed financial statements and exhibits as part of this 8-K filing. The specific details of the agreement and financial information are not fully disclosed in the provided text.
Why It Matters
This filing indicates a significant new agreement for Sage Therapeutics, which could impact its future business operations and financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, and the lack of specific details in this excerpt necessitates a medium risk assessment.
Key Players & Entities
- Sage Therapeutics, Inc. (company) — Registrant
- June 13, 2025 (date) — Date of earliest event reported
- 55 Cambridge Parkway (location) — Principal executive offices address
- Cambridge, MA 02142 (location) — Principal executive offices address
- 001-36544 (other) — Commission File Number
FAQ
What type of material definitive agreement did Sage Therapeutics, Inc. enter into?
The provided text states that Sage Therapeutics, Inc. entered into a 'Material Definitive Agreement' but does not specify the nature or terms of the agreement.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on June 13, 2025.
What is the principal executive office address for Sage Therapeutics, Inc.?
The principal executive office address for Sage Therapeutics, Inc. is 55 Cambridge Parkway, Cambridge, MA 02142.
What is the Commission File Number for Sage Therapeutics, Inc.?
The Commission File Number for Sage Therapeutics, Inc. is 001-36544.
What items are covered in this 8-K filing?
This 8-K filing covers 'Entry into a Material Definitive Agreement', 'Regulation FD Disclosure', and 'Financial Statements and Exhibits'.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 16, 2025 regarding Sage Therapeutics, Inc..